CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 250 enrolled
Drug / intervention
Impact (R) Enteral Nutrition +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00333099
NCT00333099Phase 4Completed

Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer

University Hospital, Clermont-Ferrand·interventional·Posted Jun 2, 2006·Updated Sep 14, 2012

In Brief

A Phase 4 clinical trial evaluating Impact (R) Enteral Nutrition and impact for Malnutrition and 2 related conditions. Completed, enrolled 250 participants across 1 site.

Detailed Summary

The aim of this study is to investigate if enteral immunonutrition of head and neck or esophageal cancer patients, using an arginine, omega 3 fatty acid, nucleotides-enhanced diet \[Impact (R), Novartis\] versus a standard enteral nutrition (control, Novartis), could improve clinical outcomes (mucositis frequency, treatment tolerance), nutritional and immune status, and life quality parameters.

Study Details

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2006
Enrollment StartMay 1, 2006
Primary CompletionSep 1, 2010
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.1 years ago

Interventions

Impact (R) Enteral Nutritiondietary

mucositis frequency, treatment tolerance

impactother

1500 calories every day : -5 days before the begining of the chemoradiotherapy and until the last day of the treatment